Lizhi Hu

Dr. Lizhi Hu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Aging Cell
Verified
Journal Article
Open access
JZJing Zhang
Jing Zhang
HYHaoyue Yu
Haoyue Yu
MMMao-Qiang Man
Mao-Qiang Man
LHLizhi Hu
Lizhi Hu
Skin aging is characterized by changes in its structural, cellular, and molecular components in both the epidermis and dermis. Dermal aging is distinguished by reduced dermal thickness, increased wrinkles, and a sagging appearance. Due to intrinsic or extrinsic factors, accumulation of excessive reactive oxygen species (ROS) triggers a series of aging events, including imbalanced extracellular matrix (ECM) homeostasis, accumulation of senescent fibroblasts, loss of cell identity, and chronic inflammation mediated by senescence‐associated secretory phenotype (SASP). These events are regulated by signaling pathways, such as nuclear factor erythroid 2‐related factor 2 (Nrf2), mechanistic target of rapamycin (mTOR), transforming growth factor beta (TGF‐β), and insulin‐like growth factor 1 (IGF‐1). Senescent fibroblasts can induce and accelerate age‐related dysfunction of other skin cells and may even cause systemic inflammation. In this review, we summarize the role of dermal fibroblasts in cutaneous aging and inflammation. Moreover, the underlying mechanisms by which dermal fibroblasts influence cutaneous aging and inflammation are also discussed.

5 February 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YLYingxi Li
Yingxi Li
JWJiangmei Wu
Jiangmei Wu
YTYao Tian
Yao Tian
QZQianyu Zhu
Qianyu Zhu
YGYicheng Ge
Yicheng Ge
LHLizhi Hu
Lizhi Hu

15 March 2022 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JHJunkai Huang
Junkai Huang
XFXiaoyue Feng
Xiaoyue Feng
JZJie Zeng
Jie Zeng
SZShuchang Zhang
Shuchang Zhang
JZJing Zhang
Jing Zhang
LHLizhi Hu
Lizhi Hu
NF-erythroid 2–related factor 2 (Nrf2) is a major transcription factor to protect cells against reactive oxygen species (ROS) and reactive toxicants. Meanwhile, Nrf2 can inhibit contact dermatitis through redox-dependent and -independent pathways. However, the underlying mechanisms of how Nrf2 mediates irritant contact dermatitis (ICD) are still unclear. In this article, we elucidated the role of Nrf2 in 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced acute ICD. Our study demonstrated that the ear thickness, redness, swelling, and neutrophil infiltration were significantly increased, accompanied by increased expression of inflammatory cytokines (IL-1α, IL-1β, IL-6, etc.) and decreased expression of antioxidant genes (HO-1 and NQO1) in Nrf2 knockout mice. Moreover, ERK phosphorylation was elevated in mouse embryonic fibroblasts (MEFs) from Nrf2 knockout mouse. Inhibition of ERK significantly alleviated TPA-induced cutaneous inflammation and ROS accumulation in MEFs derived from mouse. Conversely, ROS scavenging inhibited the ERK activation and TPA-induced inflammation in MEFs. Taken together, the findings illustrate the key role of the Nrf2/ROS/ERK signaling pathway in TPA-induced acute ICD. Key Points Nrf2 deficiency aggravates inflammatory response in ICD. Nrf2 plays a critical role in ICD through the HO-1/NQO1–ROS–ERK pathway.

1 February 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YGYicheng Ge
Yicheng Ge
JLJing Luo
Jing Luo
DLDan Li
Dan Li
CLChenxi Li
Chenxi Li
JHJunkai Huang
Junkai Huang
LHLizhi Hu
Lizhi Hu

8 March 2023 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YLYingxi Li
Yingxi Li
LLLin Li
Lin Li
YTYao Tian
Yao Tian
JLJing Luo
Jing Luo
JHJunkai Huang
Junkai Huang
LHLizhi Hu
Lizhi Hu
Background: Psoriasis is a common, chronic and relapsing immune-related inflammatory dermal disease. Patients with psoriasis suffering from the recurrences is mainly caused by immune response disorder. Thus, our study is aimed to identify novel immune subtypes and select targeted drugs for the precision therapy in different subtypes of psoriasis. Methods: Differentially expressed genes of psoriasis were identified from the Gene Expression Omnibus database. Functional and disease enrichment were performed by Gene Set Enrichment Analysis and Disease Ontology Semantic and Enrichment analysis. Hub genes of psoriasis were selected from protein–protein interaction networks using Metascape database. The expression of hub genes was validated in human psoriasis samples by RT-qPCR and immunohistochemistry. Further, novel immune subtypes of psoriasis were identified by ConsensusClusterPlus package and its association with hub genes were calculated. Immune infiltration analysis was performed, and its candidate drugs were evaluated by Connectivity Map analysis. Results: 182 differentially expressed genes of psoriasis were identified from GSE14905 cohort, in which 99 genes were significantly up-regulated and 83 genes were down-regulated. We then conducted functional and disease enrichment in up-regulated genes of psoriasis. Five potential hub genes of psoriasis were obtained, including SOD2, PGD, PPIF, GYS1 and AHCY. The high expression of hub genes was validated in human psoriasis samples. Notably, two novel immune subtypes of psoriasis were determined and defined as C1 and C2. Bioinformatic analysis showed C1 and C2 had different enrichment in immune cells. Further, candidate drugs and mechanism of action that applicable to different subtypes were evaluated. Conclusions: Our study identified two novel immune subtypes and five potential hub genes of psoriasis. These findings might give insight into the pathogenesis of psoriasis and provide effective immunotherapy regimens for the precise treatment of psoriasis.

1 February 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
XZXiaolong Zhu
Xiaolong Zhu
YSYue Sun
Yue Sun
XMXin Mu
Xin Mu
PGPan Guo
Pan Guo
FGFei Gao
Fei Gao
LHLizhi Hu
Lizhi Hu